—MeMed BV Flex™ simultaneously measures multiple host proteins, paired with machine learning, to deliver highly accurate results in 15 minutes from just a few drops of blood— —Designed for use in ...
Licensing Agreement to add MeMed BV™, Immune System Based Protein Signature Test for Distinguishing between Bacterial vs. Viral Infections, to the broad DiaSorin LIAISON Ò test menu, available on ...
ANDOVER, Mass. & HAIFA, Israel--(BUSINESS WIRE)--MeMed, a leader in host-response diagnostics, today announced the addition of three distinguished experts to its advisory board to accelerate its ...
MeMed Diagnostics, a Haifa-based firm that develops diagnostic solutions to monitor the body’s immune state, has received United States Food and Drug Administration (FDA) 510(k) clearance for a test ...
FDA Grants Breakthrough Device Designation to MeMed Severity Test for Patients with Suspected Sepsis
-Major Development Milestone Reinforces MeMed’s Leadership in Host-Response Diagnostics- -FDA Endorsement Accelerates Product Development and Market Readiness- ANDOVER, Mass. & HAIFA, Israel–(BUSINESS ...
MeMed today announced the completion of a new round of financing totaling over $70 million, with participation from new and existing investors including Ping An Global Voyager Fund, Foxconn, Caesarea ...
Beckman Coulter Diagnostics and MeMed have announced a strategic partnership to jointly develop and commercialize the proven MeMed BV ® test, a host immune response diagnostic that is able to ...
MeMed is a data-driven company, producing high-quality clinical evidence which is analyzed by cutting-edge AI and machine learning capabilities. The value MeMed brings lies in taking these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results